The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease
Abstract
Purpose: Histiocytoses are rare disorders with heterogeneous prognosis. BRAF V600E mutations have been observed in half of patients with Langerhans cell histiocytosis (LCH) and in 50% to 100% of patients with Erdheim-Chester disease (ECD) patients. We recently reported short-term efficacy of a BRAF inhibitor (vemurafenib) in three patients with multisystemic ECD. Patients and Methods: Vemurafenib was given to eight patients with multisystemic ECD with CNS and/or cardiac involvement. All patients were refractory to first-line treatment and harbored a BRAF V600E mutation. Four patients also had LCH lesions. Positron emission tomography (PET) scan response at month 6 was used as the main evaluation criterion. Secondary evaluation criteria were comparison at baseline and at last visit of PET and of cardiovascular and cerebral infiltrations (computed tomography scan and magnetic resonance imaging [MRI]). Results: All patients were partial metabolic responders at 6 months of vemurafenib, and the median reduction in maximum standardized uptake value was 63.5% (range, 41.3% to 86.9%). Evaluation of cardiac and aortic infiltrations showed that seven patients had a partial response and one patient had stable disease according to surface measurements derived from RECIST criteria. The four patients with infratentorial CNS infiltration had an objective decrease of the lesions on MRI. All patients had an improvement of general symptoms and a persistent response to vemurafenib, with a median follow-up time of 10.5 months (range, 6 to 16 months). Skin adverse effects were frequent and severe. Conclusion: Vemurafenib has an objective and sustained efficacy in BRAF V600E-mutated ECD as second-line therapy. In contrast to melanoma, no resistance has emerged to date after 6 to 16 months.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720
From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors
Wahl, R. L., Jacene, H., Kasamon, Y., & Lodge, M. A. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.057307 · Cited by 3,777
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569
Recurrent BRAF mutations in Langerhans cell histiocytosis
Badalian-Very, G., Vergilio, J.-A., Degar, B. A., MacConaill, L. E., Brandner, B., Calicchio, M. L., Kuo, F. C., Ligon, A. H., Stevenson, K. E., Kehoe, S. M., et al. (2010) · Blood · doi:10.1182/blood-2010-04-279083 · Cited by 1,243
Haroche, J., Charlotte, F., Arnaud, L., von Deimling, A., Hélias-Rodzewicz, Z., Hervier, B., Cohen-Aubart, F., Launay, D., Lesot, A., Mokhtari, K., et al. (2012) · Blood · doi:10.1182/blood-2012-05-430140 · Cited by 696
Self-citationA Systematic Review of the Factors Affecting Accuracy of SUV Measurements
Adams, M. C., Turkington, T. G., Wilson, J. M., & Wong, T. Z. (2010) · American Journal of Roentgenology · doi:10.2214/ajr.10.4923 · Cited by 662
Jerusalem, G., Beguin, Y., Fassotte, M. F., Najjar, F., Paulus, P., Rigo, P., & Fillet, G. (1999) · Blood · doi:10.1182/blood.v94.2.429 · Cited by 565
Haroche, J., Cohen-Aubart, F., Emile, J.-F., Arnaud, L., Maksud, P., Charlotte, F., Cluzel, P., Drier, A., Hervier, B., Benameur, N., et al. (2013) · Blood · doi:10.1182/blood-2012-07-446286 · Cited by 537
Self-citationAscierto, P. A., Minor, D., Ribas, A., Lebbe, C., O'Hagan, A., Arya, N., Guckert, M., Schadendorf, D., Kefford, R. F., Grob, J.-J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.8691 · Cited by 432
Chester, W. (1930) · Virchows Archiv für Pathologische Anatomie und Physiologie und für Klinische Medizin · doi:10.1007/bf01942684 · Cited by 415
Cited by
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Dacic, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,520
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
Emile, J.-F., Abla, O., Fraitag, S., Horne, A., Haroche, J., Donadieu, J., Requena-Caballero, L., Jordan, M. B., Abdel-Wahab, O., Allen, C. E., et al. (2016) · Blood · doi:10.1182/blood-2016-01-690636 · Cited by 1,591
Self-citationAllen, C. E., Merad, M., & McClain, K. L. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1607548 · Cited by 570
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Diamond, E. L., Durham, B. H., Haroche, J., Yao, Z., Ma, J., Parikh, S. A., Wang, Z., Choi, J., Kim, E., Cohen-Aubart, F., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0913 · Cited by 535
Self-citationGoyal, G., Heaney, M. L., Collin, M., Cohen-Aubart, F., Vaglio, A., Durham, B. H., Hershkovitz-Rokah, O., Girschikofsky, M., Jacobsen, E. D., Toyama, K., et al. (2020) · Blood · doi:10.1182/blood.2019003507 · Cited by 416
Self-citationDiamond, E. L., Subbiah, V., Lockhart, A. C., Blay, J.-Y., Puzanov, I., Chau, I., Raje, N. S., Wolf, J., Erinjeri, J. P., Torrisi, J., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.5029 · Cited by 413
Rodriguez-Galindo, C., & Allen, C. E. (2020) · Blood · doi:10.1182/blood.2019000934 · Cited by 361
The distribution of BRAF gene fusions in solid tumors and response to targeted therapy
Ross, J. S., Wang, K., Chmielecki, J., Gay, L., Johnson, A., Chudnovsky, J., Yelensky, R., Lipson, D., Ali, S. M., Elvin, J. A., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.29825 · Cited by 351
Héritier, S., Emile, J.-F., Barkaoui, M.-A., Thomas, C., Fraitag, S., Boudjemaa, S., Renaud, F., Moreau, A., Peuchmaur, M., Chassagne-Clément, C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.65.9508 · Cited by 342
Self-citationMutually exclusive recurrent KRAS and MAP2K1 mutations in Rosai–Dorfman disease
Garces, S., Medeiros, L. J., Patel, K. P., Li, S., Pina-Oviedo, S., Li, J., Garces, J. C., Khoury, J. D., & Yin, C. C. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.55 · Cited by 299
Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy
Brastianos, P. K., Shankar, G. M., Gill, C. M., Taylor-Weiner, A., Nayyar, N., Panka, D. J., Sullivan, R. J., Frederick, D. T., Abedalthagafi, M., Jones, P. S., et al. (2016) · Journal of the National Cancer Institute · doi:10.1093/jnci/djv310 · Cited by 258
Fetal‐derived immune cells at the roots of lifelong pathophysiology
Mass, E., & Gentek, R. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.648313 · Cited by 47
Metadata
- Authors
- Haroche, J., Cohen-Aubart, F., Emile, J.-F., Maksud, P., Drier, A., Tolédano, D., Barete, S., Charlotte, F., Cluzel, P., Donadieu, J., Benameur, N., Grenier, P. A., Besnard, S., Ory, J.-P., Lifermann, F., Idbaih, A., Granel, B., Graffin, B., Hervier, B., Arnaud, L., & Amoura, Z.
- Venue
- Journal of Clinical Oncology
- Published
- 2015-02-10
- Volume
- 33
- Issue
- 5
- Pages
- 411-418
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2106451155
- Cited by
- 289
- References
- 24
- FWCI
- 20.99
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.